Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease
Authors
Keywords
-
Journal
Translational Oncology
Volume 14, Issue 8, Pages 101115
Publisher
Elsevier BV
Online
2021-05-14
DOI
10.1016/j.tranon.2021.101115
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain
- (2020) Shihong Peng et al. CELL BIOLOGY AND TOXICOLOGY
- Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
- (2020) Yingming Li et al. CLINICAL CANCER RESEARCH
- Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors
- (2020) Yezi Zhu et al. ONCOGENE
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sequence specific suppression of androgen receptor–DNA binding in vivo by a Py-Im polyamide
- (2019) Alexis A Kurmis et al. NUCLEIC ACIDS RESEARCH
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography.
- (2019) Christian Zurth et al. JOURNAL OF CLINICAL ONCOLOGY
- Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
- (2019) Tatsuo Sugawara et al. INTERNATIONAL JOURNAL OF CANCER
- AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer
- (2019) Marzia Del Re et al. BJU INTERNATIONAL
- Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer
- (2019) Christof Bernemann et al. CLINICAL CANCER RESEARCH
- ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals
- (2019) Chi-Ping Huang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
- (2019) Suriyan Ponnusamy et al. CLINICAL CANCER RESEARCH
- Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
- (2019) Carlo Cattrini et al. Cancers
- 503PEPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
- (2019) R Le Moigne et al. ANNALS OF ONCOLOGY
- Androgen receptor (AR) degradation enhancer ASC-J9 ® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth
- (2018) Max A. Cheng et al. CANCER LETTERS
- ASC-J9 ® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3
- (2018) WanYing Lin et al. CANCER LETTERS
- A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer
- (2018) David Y. Takeda et al. CELL
- HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer
- (2018) Mohammad Alyamani et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
- (2018) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Determination of pKa(s) of nilutamide through UV-visible spectroscopy
- (2018) Fernando V.L. Silva et al. MICROCHEMICAL JOURNAL
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer
- (2018) Kush Dalal et al. CANCER LETTERS
- Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY
- (2018) Scott T Tagawa et al. CLINICAL CANCER RESEARCH
- Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
- (2017) Larysa H.M. Rydzewska et al. EUROPEAN JOURNAL OF CANCER
- Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression
- (2017) Ronghao Wang et al. EUROPEAN UROLOGY
- LC–MS/MS-ESI method for simultaneous quantification of darolutamide and its active metabolite, ORM-15341 in mice plasma and its application to a pharmacokinetic study
- (2017) Sreekanth Dittakavi et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions
- (2017) Kush Dalal et al. MOLECULAR CANCER THERAPEUTICS
- Quantitative proteomics reveals that long non-coding RNA MALAT1 interacts with DBC1 to regulate p53 acetylation
- (2017) Ruibing Chen et al. NUCLEIC ACIDS RESEARCH
- Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF
- (2017) Ken-ichi Takayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy†
- (2017) Nancy L Goicochea et al. PROTEIN ENGINEERING DESIGN & SELECTION
- The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells
- (2017) Francesco Morra et al. Oncotarget
- EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor
- (2016) Eva De Mol et al. ACS Chemical Biology
- Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis
- (2016) Sameer S. Udhane et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Emerging data on androgen receptor splice variants in prostate cancer
- (2016) Subing Cao et al. ENDOCRINE-RELATED CANCER
- Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain
- (2016) Carmen A. Banuelos et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
- (2016) David F. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
- (2016) Jason W D Hearn et al. LANCET ONCOLOGY
- The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
- (2016) Stefan Prekovic et al. MOLECULAR CANCER THERAPEUTICS
- Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay
- (2016) Jung Wook Park et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line
- (2016) Mojgan Shourideh et al. PROSTATE
- Identification of the Additional Mitochondrial Liabilities of 2-Hydroxyflutamide When Compared With its Parent Compound, Flutamide in HepG2 Cells
- (2016) Amy L. Ball et al. TOXICOLOGICAL SCIENCES
- Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
- (2016) Julia Hoefer et al. Oncotarget
- Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
- (2016) Chengfei Liu et al. Oncotarget
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
- (2016) Howard I. Scher et al. JAMA Oncology
- Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
- (2015) D. Xu et al. CANCER RESEARCH
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic Drug Interaction Studies with Enzalutamide
- (2015) Jacqueline A. Gibbons et al. CLINICAL PHARMACOKINETICS
- Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target
- (2015) Mohammad Asim et al. JNCI-Journal of the National Cancer Institute
- Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations
- (2015) Hongli Liu et al. Molecular BioSystems
- Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression
- (2015) Z. Shang et al. MOLECULAR CANCER THERAPEUTICS
- Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
- (2015) Zhenfei Li et al. NATURE
- Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition
- (2015) Chengfei Liu et al. PROSTATE
- EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer
- (2015) Lucas J. Brand et al. Oncotarget
- Evolutionary Fate of the Androgen Receptor−Signaling Pathway in Ray-Finned Fishes with a Special Focus on Cichlids
- (2015) Thibault Lorin et al. G3-Genes Genomes Genetics
- Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target
- (2015) Mohammad Asim et al. JNCI-Journal of the National Cancer Institute
- ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors
- (2015) Shinichi Yamashita et al. NEOPLASIA
- Androgen receptor: structure, role in prostate cancer and drug discovery
- (2014) MH Eileen Tan et al. ACTA PHARMACOLOGICA SINICA
- Human androgen deficiency: insights gained from androgen receptor knockout mouse models
- (2014) JeffreyD Zajac et al. ASIAN JOURNAL OF ANDROLOGY
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)
- (2014) PAUL TOREN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer
- (2014) Kush Dalal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- The impact of antiandrogen 2-hydroxyflutamide on the expression of steroidogenic enzymes in cultured porcine ovarian follicles
- (2014) Malgorzata Duda et al. MOLECULAR BIOLOGY REPORTS
- Tumor clone dynamics in lethal prostate cancer
- (2014) S. Carreira et al. Science Translational Medicine
- The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer
- (2014) Cynthia C. T. Sprenger et al. Hormones & Cancer
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
- (2013) Kai-Hsiung Chang et al. CELL
- Mechanisms of the androgen receptor splicing in prostate cancer cells
- (2013) L L Liu et al. ONCOGENE
- TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer
- (2013) M. D. Nyquist et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells
- (2012) Kuo-Pao Lai et al. AMERICAN JOURNAL OF PATHOLOGY
- The role of BRCA1 and BRCA2 in prostate cancer
- (2012) Elena Castro et al. ASIAN JOURNAL OF ANDROLOGY
- The Androgen Receptor Induces a Distinct Transcriptional Program in Castration-Resistant Prostate Cancer in Man
- (2012) Naomi L. Sharma et al. CANCER CELL
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Allosteric Conversation in the Androgen Receptor Ligand-Binding Domain Surfaces
- (2012) Solène Grosdidier et al. MOLECULAR ENDOCRINOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism of Androgen Receptor Antagonism by Bicalutamide in the Treatment of Prostate Cancer
- (2011) D. J. Osguthorpe et al. BIOCHEMISTRY
- Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression
- (2011) Y. Li et al. CANCER RESEARCH
- Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
- (2011) Gerhardt Attard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities
- (2011) Rong Hu et al. PROSTATE
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells
- (2010) L. Ni et al. MOLECULAR AND CELLULAR BIOLOGY
- Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
- (2010) William R. Foster et al. PROSTATE
- Non-competitive androgen receptor inhibition in vitro and in vivo
- (2009) J. O. Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens
- (2009) Jinming Zhou et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
- (2008) Ashley R. Schneekloth et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started